Canada Pension Plan Investment Board Makes New $347,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Canada Pension Plan Investment Board purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 4,100 shares of the company's stock, valued at approximately $347,000.

Several other institutional investors and hedge funds also recently bought and sold shares of AXSM. Geode Capital Management LLC lifted its position in shares of Axsome Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock worth $77,228,000 after acquiring an additional 4,079 shares in the last quarter. Invesco Ltd. increased its holdings in Axsome Therapeutics by 10.8% during the 4th quarter. Invesco Ltd. now owns 692,464 shares of the company's stock worth $58,589,000 after acquiring an additional 67,285 shares during the period. Norges Bank bought a new position in shares of Axsome Therapeutics in the fourth quarter worth $34,100,000. Charles Schwab Investment Management Inc. increased its stake in Axsome Therapeutics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock worth $27,755,000 after acquiring an additional 5,438 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock worth $19,062,000 after purchasing an additional 27,534 shares during the last quarter. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Stock Performance

Shares of NASDAQ:AXSM opened at $106.27 on Friday. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The company has a 50-day moving average price of $115.54 and a 200-day moving average price of $102.96. The company has a market cap of $5.18 billion, a price-to-earnings ratio of -17.74 and a beta of 0.88. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. As a group, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Upgrades and Downgrades

AXSM has been the topic of a number of research analyst reports. Morgan Stanley increased their price target on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Robert W. Baird raised their price target on Axsome Therapeutics from $132.00 to $160.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Jefferies Financial Group initiated coverage on Axsome Therapeutics in a report on Monday, April 7th. They set a "buy" rating and a $200.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 target price for the company. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $169.80.

Insider Activity at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.40% of the stock is owned by corporate insiders.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.